Mavacamten/Camzyos

Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS ...

... CAMZYOS (mavacamten). CAMZYOS® (mavacamten) is the first and only cardiac myosin inhibitor approved in the U.S., indicated for the treatment ...

Mavacamten Capsules (Camzyos) - Relias Media

Mavacamten reduces systolic EF and may lead to heart failure caused by systolic dysfunction.1 The patient's clinical status and LVEF should be ...

Mavacamten for treating symptomatic obstructive hypertrophic ...

Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

Mavacamten - Bristol Myers Squibb - AdisInsight - Springer

Mavacamten - Bristol Myers Squibb. Alternative Names: BMS-986427; CAMZYOS; Camzyos; HCM 1; MAVA-Bristol Myers Squibb/Myokardia; MYK 461; SAR-439152.

FDA Approves Mavacamten for Hypertrophic Cardiomyopathy

The FDA has approved Bristol Myers Squibb's Camzyos (mavacamten) for the treatment of adults with obstructive hypertrophic cardiomyopathy (HCM).

Louisiana Medicaid

Camzyos (mavacamten) [package insert]. Brisbane, CA: MyoKardia, Inc; June 2023. https://packageinserts.bms.com/pi/pi_camzyos.pdf. Ommen SR, Mital S, Burke MA ...

Camzyos (mavacamten) - Meet Molina Healthcare

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific ...

Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With ...

The EXPLORER-HCM trial showed that mavacamten was superior to placebo at improving exercise capacity and health status.

Bristol Myers bags FDA nod for blockbuster-to-be cardio drug ...

... Camzyos a green light to treat symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM). Formerly known as mavacamten, the drug ...

Camzyos: Side Effects, Cost, Dosage, and More - Healthline

Camzyos (mavacamten) is a prescription drug that's used in certain adults with obstructive hypertrophic cardiomyopathy (HCM).

CP.PMN.272 Mavacamten (Camzyos)

Mavacamten (Camzyos®) is a cardiac myosin inhibitor. FDA Approved Indication(s). Camzyos is indicated for the treatment of adults with ...

Annotation of EMA Label for mavacamten and CYP2C19 - PharmGKB

Annotation. Excerpts from the Mavacamten (CAMZYOS) EPAR: Patients should be genotyped for Cytochrome P450 (CYP) 2C19 (CYP2C19) in ...

Summary Basis of Decision for Camzyos

The following information relates to the new drug submission for Camzyos. Mavacamten. Drug Identification Number (DIN):. DIN 02532549 - 2.5 mg mavacamten, ...

Cardiology – Camzyos - Cigna Healthcare

Camzyos. Cardiology – Camzyos. • Camzyos® (mavacamten capsules - MyoKardia/Bristol Myers Squibb). INSTRUCTIONS FOR USE. The following Coverage Policy applies to ...

mavacamten (Camzyos)® RMP Summary - Swissmedic

CAMZYOS is authorised for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult ...

Consumer Medicine Information - Camzyos - Medsinfo

Camzyos contains the active ingredient mavacamten. Camzyos is used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM).

Updates from CLEAR Outcomes and VALOR-HCM - Consult QD

Additional analyses of two major multicenter trials of newer cardiovascular medications — bempedoic acid (Nexletol®) and mavacamten (Camzyos®) — ...

CAMZYOS® (mavacamten) | HCP Finder

CAMZYOS is a prescription medicine used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM).

CAMZYOS™ (mavacamten)*

*Due to the risk of heart failure due to systolic dysfunction, CAMZYOS is only available through a restricted program called the CAMZYOS REMS.

FDA Approves Mavacamten for Obstructive Hypertrophic ...

The US Food and Drug Administration has approved mavacamten (Camzyos) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM).